COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
This program will explore the use of agents recently granted emergency use authorization for the management of COVID-19. Clinicians will learn about the mechanism of action of monoclonal antibodies against COVID-19, how to identify patients who are at risk for developing severe COVID-19, and discuss best practices on incorporating these agents into clinical practice to prevent the development of severe COVID-19 in recently diagnosed patients. This activity will also explore the use of baricitinib in combination with remdesivir for patients hospitalized with COVID-19 and provide guidance on how to select patients who would benefit from this therapy.
Release Date: December 23, 2020
Expiration Date: December 23, 2021